A Researcher Live Series

Key Advances in Bioconjugation

 

January - February 2022

#BioconjugationLIVE

Register now for free

Programme

Topic Date
The development of protein-nanomaterial conjugates and their applications in therapeutics and diagnostics with Dr Daniel Richards 17th January 4pm GMT
Novel methods for the modification of cysteines and disulfides on peptides and proteins with Dr Vijay Chudasama

20th January 4pm GMT

 From Idea to IND: the importance of ADC developability with Dr João Nunes 3rd February 4pm GMT

 


Supported by: 

 

bio-techne_logo

Hear from industry experts

Join our speakers for discussions and Q&A about their latest research and discoveries


vijay (1)

Novel methods for the modification of cysteines and disulfides on peptides and proteins with Dr Vijay Chudasama

Prof. Vijay Chudasama is a research group leader at UCL, a holder of a number of prestigious awards, including the Ramsay Medal (2011), 1st Prize at Final Year Organic Chemistry and Chemical Biology PhD Presentation Competition (2011),  Lilly Postgraduate Prize Day (2010), 1st Prize at UCL Chemistry Postgraduate Poster Competition (2010)  and UCL Graduate School Research Scholarship (2008, 2009, 2010). He has been highlighted as a future leader in Science by Forbes magazine and the Royal Society of Chemistry.

In 2016, Vijay was cited as being one of CNN News’ 2020 visionaries for his work in the field of antibody-drug conjugates before being promoted to a Reader position at UCL in the section of Organic Chemistry & Chemical Biology. In 2017, Prof. Chudasama was highlighted by GSK at their prestigious GSK Emerging Academics Symposium for his work on the treatment of cancer. He was then selected as the 2018 Howard Prize Lecturer, which celebrates world-leading mid-career academics working in the biophysical sciences (BSI).

Most recently, in late 2019, he was promoted to Professor of Organic Chemistry and Chemical Biology at UCL. He has close to 100 publications.


Joao (1)

From Idea to IND: the importance of ADC developability with Dr João Nunes

Dr João P. M. Nunes is a Senior Scientist at Abzena, a life sciences group with its headquarters in San Diego, California which provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and ADC drug development services in the pharmaceutical industry. He specialises in the conjugation of cytotoxic drugs to antibodies for the development of early drug discovery antibody-drug conjugates and has co-authored 17 scientific publications. Dr João P. M. Nunes holds a PhD in Organic Chemistry, has developed two methods for the synthesis of bifunctionalised cyclopentenones and synthesised over 40 novel compounds. He had over 15 years of research across multiple projects in Bioconjugation, Organic Chemistry and Coordination Chemistry. 


daneil

The development of protein-nanomaterial conjugates and their applications in therapeutics and diagnostics with Dr Daniel Richards

Dr Daniel Richards is a co-investigator on the BRCCH-funded DAVINCI project and will be leading the effort at ETH Zurich to develop a smartphone app capable of analysing and interpreting the project’s SARS-CoV-2 test. Dr Richards joined the deMello group at ETH Zurich as a Marie Skłodowska-Curie Fellow in early 2020 and has since focused on exploring the interface of synthetic biology, diagnostics and microfluidics. He has an active interest in point-of-care diagnostics, protein modification, synthetic biology and nanomaterials. Prior to joining ETH Zurich, Dr Richards was a postdoctoral researcher at Imperial College London, UK, where he was involved in developing nanomaterial-based diagnostic technologies for both infectious and non-infectious diseases. He completed his PhD at University College London, where he focused on applying novel chemical reactions to complex proteins with the aim of improving the functionality of therapeutically relevant biomolecules.